A New Paradigm for Patient Recruitment
Leveraging Medical Laboratory Data for Patient Recruitment
GHENT, Belgium--(BUSINESS WIRE)-- Cerba Research, a leading healthcare diagnostic company and wholly owned subsidiary of Cerba Healthcare, today announced a new partnership with Biokortex, a provider of digital solutions to the healthcare sector. This partnership will leverage patient biological and medical data to support drug developers and CROs with patient identification and recruitment activity.
“Cerba Healthcare and Cerba Research are committed to investing in technologies that will reduce the patient burden of participating in clinical trials and help our clients to accelerate their development strategy. Biokortex will allow them to prospectively identify potential patients and offer them a safer alternative to access innovative treatments,” said Mario Papillon, CEO at Cerba Research.
“Digitization is providing an impetus to move away from centralized, high-cost, and difficult-to-access settings to more virtual, patient-centric, and efficient clinical trials models. Cerba Healthcare is the perfect partner to build the future patient's care path,” said Biokortex CEO Adrien Ko.
The benefits of this new partnership include:
- Leveraging patients’ biological and medical data — as well as biomarker and genetic data from the Cerba Healthcare network — which comprises over 25 million patients per year from over 1,000 sites located in Europe, Africa, and North America
- A global footprint with data on global testing, frequency, and accuracy
- A platform for screening and companion diagnostic testing across Europe and Africa
- Connecting real-world laboratory data from clinical sites and digitizing patient data, this partnership will optimize patient recruitment for precision medicine by identifying patients expected to respond to your product — moving efficiently into clinical trials and allowing patients to receive information on new therapies at the right time
About Cerba Research
Cerba Research is a leading healthcare diagnostic company with end-to-end drug development and diagnostic solutions to optimize R&D drug productivity and commercialization, providing global clinical trial central laboratory solutions (speciality lab, FCM, ICH, NGS, BioA, metabolomics), translational science (biomarkers development, CDx, biobanking), and IVD (biospecimens, prospective sample collection, IVD evaluation).
About Cerba Healthcare
Cerba Healthcare, the parent company of Cerba Research, is an international network of medical, biological laboratories operating in private and public sectors, providing doctors, medical biology test laboratories, and pharmaceutical companies a comprehensive offer in terms of biological diagnosis from the local laboratory to the hyperspecialized biology laboratory.
Biokortex provides IT solutions for process improvement in medical research, connecting the players of the medical world and bringing digital solutions to current unmet needs. Biokortex is the result of the founding team's experience and numerous interactions with stakeholders about collaborative work organization and the digitization of medicine. Biokortex is positioned as a key advising company in digital strategy for medicine and its industrialized forms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005297/en/
Adrien Ko, Biokortex
Sofie Vandevyver, Cerba Research
Phone Number +32 9 329 23 29
Source: Cerba Research
View this news release online at: